| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Pathology/Laboratory for Exp. Patho-Oncology [F. M., A. J. M. G., J. W. O., L. H. J. L.] and Pathology/Molecular Diagnostics [W. D.], University Hospital Rotterdam/Daniel, Josephine Nefkens Institute, 3000 DR Rotterdam, the Netherlands, and Department of Oncology, Hematology, Immunology, and Rheumatology, University of Tuebingen Medical Center, Tuebingen 72076, Germany [F. M., C. B.]
Systemic cisplatin-based chemotherapy cures
90% of patients with metastatic germ celltumors (GCTs). The biological basis of this exquisite chemo-sensitivity and the resistant phenotype encountered in 1015% of patients with GCT is yet unclear. A defective mismatch repair pathway leading to microsatellite instability (MSI) has been related to resistance to cytotoxic drugs. We investigated 100 unselected GCTs and 11 clinically defined chemotherapy-resistant GCTs for MSI using 8 mono- or dinucleotide markers and the presence of the mismatch repair factors MLH1, MSH2, and MSH6 by immunohistochemistry. The resistant tumors, both chemo-naïve (n = 8) and pretreated (n = 3), showed a significantly higher incidence of MSI compared with the unselected series (45 versus 6% in at least one locus and 36 versus 0% in
2 of 8 loci, both P
0.001). In 5 of all 11 unstable tumors, MSI correlated with immunohistochemical findings. This study demonstrates for the first time a positive correlation between MSI and treatment resistance in GCT.
This article has been cited by other articles:
![]() |
R. P. Topping, J. C. Wilkinson, and K. D. Scarpinato Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling J. Biol. Chem., May 22, 2009; 284(21): 14029 - 14039. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Honecker, H. Wermann, F. Mayer, A. J.M. Gillis, H. Stoop, R. J.L.M. van Gurp, K. Oechsle, E. Steyerberg, J. Th. Hartmann, W. N.M. Dinjens, et al. Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors J. Clin. Oncol., May 1, 2009; 27(13): 2129 - 2136. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. O'Brien and R. Brown Signalling cell cycle arrest and cell death through the MMR System Carcinogenesis, April 1, 2006; 27(4): 682 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Giacomini, S. Y. Leung, X. Chen, S. T. Yuen, Y. H. Kim, E. Bair, and J. R. Pollack A Gene Expression Signature of Genetic Instability in Colon Cancer Cancer Res., October 15, 2005; 65(20): 9200 - 9205. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mayer, F. Honecker, L. H. J. Looijenga, and C. Bokemeyer Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors Ann. Onc., June 1, 2003; 14(6): 825 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. J. Looijenga, H. Stoop, H. P. J. C. de Leeuw, C. A. de Gouveia Brazao, A. J. M. Gillis, K. E. P. van Roozendaal, E. J. J. van Zoelen, R. F. A. Weber, K. P. Wolffenbuttel, H. van Dekken, et al. POU5F1 (OCT3/4) Identifies Cells with Pluripotent Potential in Human Germ Cell Tumors Cancer Res., May 1, 2003; 63(9): 2244 - 2250. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Augusto-Pinto, S. M. R. Teixeira, S. D. J. Pena, and C. R. Machado Single-Nucleotide Polymorphisms of the Trypanosoma cruzi MSH2 Gene Support the Existence of Three Phylogenetic Lineages Presenting Differences in Mismatch-Repair Efficiency Genetics, May 1, 2003; 164(1): 117 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mayer, H. Stoop, G. L. Scheffer, R. Scheper, J. W. Oosterhuis, L. H. J. Looijenga, and C. Bokemeyer Molecular Determinants of Treatment Response in Human Germ Cell Tumors Clin. Cancer Res., February 1, 2003; 9(2): 767 - 773. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |